Line 71: |
Line 71: |
| | Anaplastic PXA, WHO grade III / Ganglioglioma, WHO Grade III | | | Anaplastic PXA, WHO grade III / Ganglioglioma, WHO Grade III |
| | '''Loss:''' monosomy 9 / 9p deletion, but no diagnostic findings | | | '''Loss:''' monosomy 9 / 9p deletion, but no diagnostic findings |
− | | '''Mutation:''' BRAF V600E less common here than in PXA, grade II | + | | '''Mutation:''' BRAF V600E less common here than in PXA, grade II<br> |
| '''Loss:''' CDKN2A/CDKN2B | | '''Loss:''' CDKN2A/CDKN2B |
| | CDKN2A/CDKN2B loss may correlate with anaplastic histology | | | CDKN2A/CDKN2B loss may correlate with anaplastic histology |
Line 79: |
Line 79: |
| |Glioblastoma, WHO grade IV | | |Glioblastoma, WHO grade IV |
| |IDH-mutant | | |IDH-mutant |
− | |'''Gain:''' 1q, 2q, 3q, 7, 16p, 17q, 21q | + | |'''Gain:''' 1q, 2q, 3q, 7, 16p, 17q, 21q<br> |
| '''Loss:''' 6q, 8q, 9p, 9q, 10q, 13q, 17p, 22q | | '''Loss:''' 6q, 8q, 9p, 9q, 10q, 13q, 17p, 22q |
| ''' Chromothripsis:''' observed | | ''' Chromothripsis:''' observed |